Lorlatinib 25mg

COMPOSITION:

EACH FILM-COATED LUCILORLA TABLET CONTAINS: Lorlatinib……………………25mg

INDICATION:

LuciLorla is a kinase inhibitor indicated for the treatment of adult patients with metastatic non- small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

DOSAGE AND USE:

Recommended dosage: 100 mg orally once daily.

Severe Renal Impairment: 75 mg orally once daily.

Tablets should be swallowed whole & not chewed or crushed.

STORAGE:

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Keep medicine out of the reach of Children.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING AND PRECAUTION:

To be sold by retail on prescription of a Registered oncologist only, and as directed by the physician.